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Abstract 
UDP-Galactopyranose mutase (UGM) is a flavin-containing enzyme that catalyses the 
reversible conversion of UDP-Galactopyranose (UDP-Galp) to UDP-Galactofuranose (UDP-
Galf) and plays a key role in the biosynthesis of the mycobacterial cell wall galactofuran. A 
soluble, active form of UGM from Mycobacterium tuberculosis (MtUGM) was obtained from a 
dual His6-MBP tagged MtUGM construct. We present the first complex structures of MtUGM 
with bound substrate UDP-Galp (both oxidized flavin and reduced flavin). In addition, we have 
determined the complex structures of MtUGM with inhibitors (UDP and the dideoxy-
tetrafluorinated analogs of both UDP-Galp (UDP-F4-Galp) and UDP-Galf (UDP-F4-Galf)), which 
represent the first complex structures of UGM with an analogue in the furanose form, as well as 
the first structures of dideoxy-tetrafluorinated sugar analogs bound to a protein. These structures 
provide detailed insight into ligand recognition by MtUGM and show a similar overall binding 
mode as reported for other prokaryotic UGMs. The binding of the ligand induces conformational 
changes in the enzyme, allowing ligand binding and active site closure. In addition, the complex 
structure of MtUGM with UDP-F4-Galf reveals the first detailed insight into how the furanose 
moiety binds to UGM. In particular, this study confirmed that the furanoside adopts a high 
energy conformation (4E) within the catalytic pocket. Moreover, these investigations provide 
structural insights to the enhanced binding of the dideoxy-tetrafluorinated sugars compared to 
unmodified analogs. These results will help in the design of carbohydrate mimetics and drug 
development, and show the enormous possibilities on the use of polyfluorination in the design of 
carbohydrate mimetics. 
  
Introduction 
Mycobacterium tuberculosis is an intracellular human pathogen that targets alveolar 
macrophages and causes tuberculosis (TB), which kills around 2 million people worldwide every 
year. M. tuberculosis also exists in extracellular environments and causes disseminated disease.1-
3 The occurrence of multidrug (MDR) and extensively drug-resistant (XDR) strains of M. 
tuberculosis have emerged that are resistant to most or all known antibiotics.4-6 Thus, there is an 
urgent need to develop new drugs against tuberculosis.  
Galactofuranose (Galf) is an essential component of the arabinogalactan that connects the 
peptidoglycan layer and the mycolic acid layer in the mycobacteria cell wall.7 One key enzyme 
involved in Galf metabolism is UDP-Galactopyranose mutase (UGM). UGM is a flavoenzyme 
that catalyzes the inter-conversion of UDP-Galactopyranose (UDP-Galp) to UDP-
Galactofuranose (UDP-Galf), the biosynthetic precursor of all galactofuranose-containing 
prokaryotic and eukaryotic glycoconjugates (Scheme 1).8-14 Deletion of the gene encoding for 
UGM in M. tuberculosis demonstrated that this enzyme is essential for mycobacterial growth.15 
Since Galf and UGM are not found in humans, UGM is a validated target for therapeutic 
intervention.14,16 
A number of groups have developed inhibitors against UGM, with varying degrees of success. 
17-24 These potential inhibitors have included mechanism-based inhibitors19,23,25-29 heterocyclic 
molecules obtained from high throughput screening of chemical libraries18,30 and substrate 
analogue inhibitors.17,20,31 UGM inhibitors have been identified that block the growth of 
mycobacterial cells18 and a pyrazole-based compound was demonstrated to possess both UGM 
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inhibitory properties and broad anti-mycobacterial activities.22 These data validated the pyrazole 
compound as a promising lead drug candidate against UGM.22 Nevertheless, a better 
understanding of the UGM substrate tolerance is required to further assist the development of 
more potent inhibitors of therapeutic value. 
Fluorosugar nucleotides have been synthesised to probe the UGM substrate specificity and the 
equilibrium position of the enzyme-catalysed reaction (Scheme 1). The 2-, 3- and 6-monofluoro-
substituted UDP-Galp analogs, as well as the 2- and 3- and 6-monofluoro-substituted UDP-Galf 
analogs were found to be substrates for UGM.32-36 In addition, UDP-D-talopyranose (C2 
hydroxyl in axial orientation) and UDP-2-deoxy-2-fluoro-D-talopyranose (2-fluoro in axial 
orientation) are not substrates of UGM.34  Recently N'Go et al.37 reported the synthesis of 
dideoxy-tetrafluorinated analogs of both UDP-Galp (UDP-2,3-dideoxy-2,2,3,3-tetrafluoro-D-
threo-hexopyranose 3, abbreviated as UDP-F4-Galp) and UDP-Galf (UDP-2,3-dideoxy-2,2,3,3-
tetrafluoro-D-threo-hexofuranose 4, abbreviated as UDP-F4-Galf) and shown that these dideoxy-
tetrafluorinated analogs are excellent inhibitors, but not substrates of UGM. The rationale for the 
introduction of this unusual fluorination motif originated from studies38,39 in which affinity gain 
is sought through a combination of favourable hydrophobic desolvation energy and atractive 
multipolar interactions of the C–F groups with protein residues (with such interactions being 
negligible in aqueous medium). Interestingly, the Kd value of 4 was determined by STD-NMR 
competition experiments to be in the low micromolar range, around 5-10 µM, depending on the 
oxidation state of the enzyme, while the corresponding UDP-3-deoxy-3-fluoro-D-galactofuranose 
5 showed a much higher Kd value (~400-600 µM).35  
In 2004, Kiessling  and coworkers characterized a covalent adduct of the FAD cofactor and a 
radiolabeled UDP-Galp by mass spectrometry after having reduced the putative iminium 
intermediate 8 with sodium cyanoborohydride (Scheme 2).8  These results strongly suggested 
that the three FAD-galactose covalent adducts 7-9 are intermediates of the reaction. Adducts 7 
and 9 can be formed either through a direct attack of the nucleophilic FADH- cofactor onto the 
oxycarbenium 6 and 10, or thanks to a preliminary SET followed by radical coupling. 
Importantly, a nucleophilic covalent attack by FAD on an anomeric carbon had not been detected 
previously.  Moreover, the iminium adduct 8 could be characterized by UV spectroscopy. These 
key experiments were further improved40,41 and applied to other UGMs,42,43 including eukaryotic 
enzymes, and always lead to the conclusion that the FAD plays the role of the catalytic 
nucleophile. This mechanism is currently the most accepted one. However, some important 
mechanistic aspects are still under debate: a direct SN2-like substitution of the UDP leaving 
group of 1 and 2 has also been proposed.44,45 If verified, the two high-energy intermediates 6 and 
10 would not be formed. Moreover, the possibility of SET has been proposed46-48 but never ruled 
out.49 
Detailed structural knowledge of the ligand-enzyme interactions is important for the design of 
specific UGM inhibitors, as well as yielding insights into the mechanistic aspects of Galf 
biosynthesis. Crystal structure studies of prokaryotic UGM have been conducted on UGM from 
Escherichia coli (EcUGM),50 Klebsiella pneumoniae (KpUGM),46 Deinococcus radiodurans 
(DrUGM)51 and Mycobacterium tuberculosis (MtUGM),46 though only DrUGM and KpUGM 
have been crystallized in the presence of pyranosides or inhibitors.40,41,51,52 Additionnally, 
structural studies have been conducted on an eukaryotic orthologue of UGM.53,54 However, in 
spite of many efforts, none of these UGMs could be crystallized with UDP-Galf or furanoside 
analogs. Therefore, the binding mode of UGM and its substrate UDP-Galf has remained elusive. 
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Given the unique mechanism of this flavoenzyme and the fact that Galf has a better affinity than 
Galp for UGM, such knowledge would aid in confirming the key catalytic principles that govern 
this rather unusual isomerisation process. 
  The structures obtained so far have revealed that the 3-dimensional fold is largely conserved 
among prokaryotic and eukaryotic UGMs. They have also provided detailed insights on the 
conserved and unique features for ligand recognition and on the structural changes observed 
upon ligand binding.55 In an effort to design antimicrobial drugs against the pathogenic organism 
M. tuberculosis, we focus our structural studies on MtUGM. In this article, we present the crystal 
structures of MtUGM in complex with its substrate, UDP-Galp, and with the inhibitors UDP, 
UDP-F4-Galp and UDP-F4-Galf. These are the first atomic resolution complex structures 
reported for MtUGM, for a complex involving a substrate with a Galf configuration, and for 
complexes involving dideoxy-tetrafluorinated sugar analogs. In particular, our structural results 
provide detailed insights on how the enzyme retains key interactions with the tetrafluorinated 
ligand 3, as compared to the natural ligand having a vicinal diol group in these positions 1. We 
anticipate that this structural knowledge will not only provide a sound basis for further 
development of a new generation of potent UGM inhibitors, but is also the cornerstone for the 
design and employment of polyfluorinated carbohydrate mimetics on a regular basis. 
 
Methods 
Cloning of MtUGM- PCR 
A pET29b plasmid containing the MtUGM gene was used as template in the Gateway 
cloning.11 In order to construct the Gateway entry clone the MtUGM gene was first PCR 
amplified according to a modified procedure described by Nalamsetty and Waugh.56 The PCR 
was performed in two separate steps using the same program cycling settings: initial melt for 5 
min at 95°C, annealing 55°C for 30 s, and elongation 72°C for 2 min; 44 cycles of 95°C for 30 s, 
55°C for 45 s, and 72°C for 1 min; 72°C for 10 min, hold at 4°C. The first PCR amplification 
reaction was carried out with two gene-specific primers, MtUGM-N1 (5’-
GAGAACCTGTACTTCCAGGGTATGCAACCGATGACC-3’) and MtUGM-C (5’-GGGGACCACTTTG 
TACAAGAAAGCTGGGTTATTATGCGCCGTCCTGAAGCAGTGG-3’) with contain 5’extensions that 
add an in-frame TEV protease recognition site and an attB2 recombination site to the MtUGM 
gene N- and C-termini, respectively. After the first PCR amplification the PCR product was gel 
purified using the QIAquick gel extraction kit, according to the manufacturer’s instructions. The 
obtained purified PCR product was then used as the template for the final PCR amplification 
with primers, N2 (5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTCGGAGAACCTGTACT TCCAG-3’) 
and MtUGM-C. Primer N2 is a generic primer56 designed to anneal to the nucleotide sequence 
encoding the TEV protease recognition site and adds the attB1 recombination site to the N-
terminus of the amplicon. The final attB-MtUGM PCR product was gel purified using the 
QIAquick gel extraction kit to remove residual attB primers.  
 
Gateway cloning 
Gateway recombinational cloning was performed according to the Gateway® Technology with 
Clonase®II manufactory manual (Invitrogen). To create the His6-MBP-MtUGM fusion vector, 
the final attB-MtUGM PCR product was first inserted by recombinational cloning using the 
Page 4 of 48
ACS Paragon Plus Environment
Journal of the American Chemical Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
5 
 
standard BP protocol (Invitrogen) into the donor vector pDONRTM221 to yield the entry clone 
intermediate. 5 µl of the BP reaction product was transformed into Library Efficiency® DH5α™ 
Competent Cells (Invitrogen) and transformants were selected on LB agar plates containing 
kanamycin. Plasmid DNA was isolated from saturated cultures grown from individual 
kanamycin resistant colonies and screened by PCR, using primers MtUGM-N1 and MtUGM-C, 
to confirm that the clones have the expected structure. DNA sequencing was performed to 
confirm the correctness of the MtUGM nucleotide sequence. Next, the entry clone intermediate 
was recombined into the cytoplasmic His6-MBP destination vector (pDEST-His6MBP) using the 
standard RL protocol (Invitrogen) to construct the His6-MBP-MtUGM overexpression vector. 5 
µl of LR reaction product was transformed into Library Efficiency® DH5α™ Competent Cells 
(Invitrogen) and transformants were selected on LB agar plates containing ampicillin. DNA 
sequencing was performed to confirm the correctness of the MtUGM nucleotide sequence. The 
His6-MBP-MtUGM overexpression vector was transformed into BL21CodonPlus™-RIL 
(Stratagene) cells and transformants were selected on LB agar plates containing both ampicillin 
(100 µg/mL) and chloramphenicol (30 µg/mL).  
 
Production of wild-type MtUGM 
 During the cloning procedure of MtUGM, a G917C point mutation was introduced, resulting 
in Pro306 to Arg306 mutation. This was initially noticed during structure refinement and later 
confirmed with DNA sequencing. Additional clones produced during the Gateway cloning step 
(above) were sequenced and a clone with no mutation was identified. This clone was then also 
expressed and purified following the procedure outlined below for the P306R mutant. 
Expression of MtUGM. 
The His6-MBP–MtUGM fusion protein was overexpressed in E. coli BL21(DE3) 
CodonPlusTM-RIL cells (Stratagene). Briefly, E. coli BL21(DE3) CodonPlusTM-RIL cells 
containing the pDest-His6-MBP-MtUGM overexpression vector were grown in 100 mL of Luria 
Broth (LB) supplemented with 100 µg/mL ampicillin, 30 µg/mL chloramphenicol and 0.4% D-
(+)-glucose monohydrate (Sigma-Aldrich). Cells were grown overnight at 37 °C and 250 rpm. 
The next day two times 1L LB media, each supplemented with 100 µg/mL ampicillin, 30 µg/mL 
chloramphenicol and 0.4% D-(+)-glucose monohydrate, was inoculated with 25 ml of the 
overnight culture. Cells were grown at 15 °C to increase the solubility of the overexpressed 
MBP-MtUGM fusion protein. When the cells reached early log phase (OD600nm = 0.3–0.5) 
isopropyl-β-D-thiogalactopyranoside (IPTG) was added to a final concentration of 1 mM. 
Twenty-six hours later cells were harvest by centrifugation at 8,000 rpm for 20 min and stored at 
-80 °C. Typically, a 2 L culture yields ~10 g of wet cell pellet. 
 
Purification of MtUGM. 
The cell pellet was re-suspended in 70 ml buffer A (25 mM Tris-HCL pH7.4 and 500 mM 
NaCl). After addition of 2 mM Lysozyme, 1 mM AEPSF, 20 µg/mL DNAse and 200 µl HaltTM 
EDTA free protease inhibitors (Thermo Scientific), the resulting cell suspension was incubated 
on ice for 30 min. The cells were ruptured by sonication with a pulse-rest cycle of 10 sec on and 
10 sec off, for a total of 3 min. Cell debris was removed by centrifugation at 20,000 rpm for 20 
minutes at 4 °C. The supernatant was filtered through a 0.22 µ filter. Per run, 15 ml of the 
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supernatant was loaded onto three tandem 5 ml MBPTrap HP columns (GE Healthcare) pre-
equilibrated with buffer A. The column was washed with 14 column volumes buffer A and 
bound His6-MBP-MtUGM fusion protein was eluted in 5 column volumes buffer B (25 mM Tris-
HCl pH 7.4 and 500 mM NaCl and 50 mM maltose). Peak fractions containing pure His6-MBP-
MtUGM fusion protein were pooled and concentrated six-fold using a 30KDa Amicon centrifuge 
filter devise. About 87 mg His6-MBP-MtUGM fusion protein was obtained from a 2L culture. 
The His6-MBP dual tag was digested overnight at 4 °C with 1 mg His6-tagged TEV protease57 
per 10 mg of fusion protein. The TEV protease-treated sample was filtered through a 0.22 µ filter 
and loaded onto a 14 ml Ni-Sepharose HP column pre-equilibrated with buffer A. The untagged 
MtUGM protein passes through the column while residual undigested His6-MBP-MtUGM fusion 
protein, His6-MBP and His6-TEV protease remained bound. The purity of the MtUGM 
containing fractions were analyzed by SDS–PAGE. To reduce the concentration of maltose in 
the MtUGM protein samples, MtUGM was washed with buffer A, through dilution and 
subsequently re-concentration. Finally, MtUGM was concentrated to 6.5 mg/ml in 25 mM Tris 
pH 7.5 and 500 mM NaCl, flash frozen in small aliquots and stored at -80 °C.  
 
Activity assay 
For kinetic experiments the protein was purified as described above, however the buffer used 
was 50mM phosphate pH 7.5 and 320 mM NaCl. Kinetic constants for MtUGM were determined 
as described previously for the kinetic assay of AfUGM53. The conversion of UDP-Galp to UDP-
Galf was monitored at 262 nm using HPLC (Agilent Technologies, 1100 Infinity). A fixed 
concentration of MtUGM (100nM) was used to have less than 40% conversion to the product 
UDP-Galp. Reactions were carried out with varying amounts of UDP-Galf (0 – 600 µM) in a 
final volume of 100 µL, 50 mM phosphate buffer pH 7.0 containing 20 mM freshly prepared 
sodium dithionite. The incubations were carried out for 2 minute at 37 °C and quenched with 100 
µl n-butanol. After centrifugation the aqueous phase was injected on a Carbopac PA1 column. 
The nucleotide sugars were eluted isocratically with 0.2M ammonium acetate pH 7.0. The 
amount of conversion was determined by integration of the UDP-Galp and UDP-Galf peaks. The 
initial velocity was calculated from the substrate concentration and percentage UDP-Galp 
conversion. Kinetic parameters were determined with GraphPad Prism software (GraphPad 
Software, San Diego, CA) using nonlinear regression analysis. All experiments were performed 
in duplicate. 
 
Crystallization of MtUGM 
Diffraction quality crystals of MtUGM complexed with the substrate UDP-Galp and 
inhibitors (UDP, UDP-F4-Galf and UDP-F4-Galp) were obtained using the Hanging drop method 
at 4 °C. For detailed description of the crystallization experiments see Supplemental Text. 
Briefly substrate/ inhibitors (final concentration of 20 mM) was added to the protein solution 
(6.5 mg/ml in 25 mM Tris pH 7.5 and 500 mM NaCl) and prior to crystallization was reduced by 
adding sodium dithionite (final concentration 20 mM). Drops (2.4 µl) were prepared by mixing 
equal volumes of protein solution (1.2 µl) and reservoir solution (1.2 µl), wells contained 0.5 ml 
crystallization solution. Plate-like crystals were obtained within 1 week using 20% PEG 3350, 
0.1 M Bis-Tris pH 5.5 and additives. Best diffracting crystals were obtained by allowing the 
crystals to grow for one month. Crystals were cryo-protected in crystallization solution 
containing 30% ethylene glycol and flash-cooled in liquid nitrogen. 
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Data collection and processing 
Datasets for MtUGM in complex with UDP, UDP-Galpox (with oxidized FAD), UDP-Galpred 
(with reduced FADH2), UDP-F4-Galp and UDP-F4-Galf were collected at beamline 08ID-1 on a 
Rayonix MX300HE X-ray detector. The data sets were processed and scaled using autoprocess58 
and d*TREK.59 The data collection statistics are shown in Table 1A. 
 
Structure determination and refinement 
The MtUGM:UDP-Galp complex structure was determined by molecular replacement using 
MOLREP60 within the CCP4 package.61 The structure solution was found by using the 
unliganded MtUGM structure (PDB code 1VOJ) as the search model.46 The unliganded MtUGM 
structure missed the loop residues 138-141. Inspection of the electron density maps showed that 
these residues could be build. Residues 135-143 were (re)build and the unliganded MtUGM 
structure was then re-refined with good geometry. This structure was used for the structural 
comparisons between the unliganded and liganded MtUGM. The MtUGM:UDP-Galp structure 
was used as the starting model for all other MtUGM complex structures (UDP, UDP-Galp(red), 
UDP-F4-Galp and UDP-F4-Galf). Refinement of all structures was done with PHENIX.62 
Initially, rigid body refinement was done, followed by simulated annealing using Cartesian 
dynamics at 5000 K to remove model bias. Iterative rebuilding of the model was done in 
COOT63 followed by simulated annealing using Cartesian dynamics at 2500 and gradually 
lowering to 1000K. NCS restraints were used throughout the refinement for all models. 
Placement of cofactor and ligands was done with ligandFit in PHENIX.62 The models for UDP-
F4-Galp and UDP-F4-Galf were generated in SKETCHER as part of CCP4 suite. Libraries for 
cofactor and ligands were generated with ELBOW in PHENIX.62 The refinement progress was 
monitored by following Rfree and inspecting the electron density maps. When Rfree dropped 
below 30%, water molecules were added using water update refinement in PHENIX, and their 
positions were manually checked using COOT. The final round of refinement was done with 
optimized refinement target weights for best geometry. Final refinement statistics are shown in 
Table 1B.  
 
 Structural analysis 
The stereochemistry of all models was validated with MOLPROBITY 64 as part of PHENIX62 
and the ADIT validation server at RCBS-Rutgers (http://deposit.pdb.org/validate). 
Superpositions were calculated with DALI-lite65 and with SUPERPOSE within the CCP4 
package.66 Superpositions of the open and closed MtUGM structures were done with 
SUPERPOSE by superimposing specific residue selections (residues 4-120 and residues 186-
395) and excluding the domain-2 mobile residues 121-185. Conformational changes due to 
Domain motions were analysed by DynDom.67 Figures were prepared with PYMOL 
(http://www.pymol.org), RASMOL68 and ESPript.69          
 
Protein Data Bank accession numbers 
Coordinates have been deposited in the PDB with accession codes: MtUGM with UDP-
Galp(ox), 4RPG; MtUGM with UDP-Galp(red),4RPH; MtUGM with UDP, 4RPJ; MtUGM with 
UDP-F4-Galp, 4RPL and MtUGM with UDP-F4-Galf, 4RPK. 
    
 
Results and discussion 
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MBP enhanced the overexpression and purification of soluble active MtUGM. 
E. coli Bl21(DE3) cells harbouring the MtUGM-pet29b expression construct for 
overexpressing N-terminal His6-MtUGM resulted in insoluble protein (inclusion bodies). We 
tried different expression vectors and E. coli hosts and used different growth temperatures. 
However, we were not able to improve the solubility of MtUGM (data not shown). The solubility 
of a recombinant protein can often be improved when fused to a highly soluble fusion partner. 
Maltose binding protein (MBP) is known to enhance the solubility of proteins when used as a 
fusion partner. 70 The His6-MBP–MtUGM fusion protein could be easily overexpressed in E. coli 
BL21(DE3) CodonPlusTM-RIL cells and purified to homogeneity by means of affinity 
chromatography. From a 2 L culture about 6 mg of pure MtUGM was obtained. The rate of 
conversion of UDP-Galf to UDP-Galp was determined at 37°C in the presence of 20 mM sodium 
dithionite. Although both MBP-MtUGM and MtUGM are active, we have only determined the 
kinetic parameters for the latter one. The structural studies were conducted using the P306R 
mutant enzyme, but we also successfully expressed and purified the wild-type enzyme. The 
kinetic parameters for the wild-type and P306R were obtained and found to be comparable to 
each other and to other prokaryotic UGMs (Table 2). These results lead us to believe that the 
P306R mutant will be structurally similar to the wild-type enzyme. 
 
Overall complex structure of MtUGM shows significant structural changes compared to 
unliganded MtUGM 
MtUGM complex structures crystallize in space group C2. The crystals contain three 
monomers in the asymmetric unit, including one non-crystallographic two-fold dimer and a 
second crystallographic two-fold dimer, formed by the third monomer and a symmetry-related 
monomer. Each monomer in the dimer is composed of the 3 characteristic UGM domains (FAD 
binding domain-1, α-helical domain-2 and β-sheet domain-3) (Figure 1A-B). Crystal structures 
of MtUGM were determined in complex with the substrate UDP-Galp (both reduced and 
oxidized flavin), with UDP (oxidized flavin), and with tetra-fluorinated analogs of both UDP-
Galp (UDP-F4-Galp) and UDP-Galf (UDP-F4-Galf)). All complex structures are highly similar 
with root mean square deviation (rmsd) for all overlapping Cα atoms of less than 0.3 Å.  
The P306R mutatant used in these studies is kinetically similar to the wild-type enzyme.   
Pro306 is located on the solvent exposed loop (His300-Lys309) connecting the small helix η3 
and beta strand β14 of the β-sheet domain (Supplemental Figure S1), over 25 Å from the FAD. 
The Cδ atom of Pro306 is 3.5 Å from the main chain oxygen of Thr53, located on the small 
sharp turn (Glu52-Gly56) connecting beta strands β3 and β4. The Pro306Arg mutation releases 
this clash and results in a 1 Å shift in the position of the two solvent exposed loops without 
effecting the position of side chains and interaction with the protein. Arg306 forms a salt bridge 
with the side chain of Asp308 and the main chain oxygen of Gln54 and replaces a salt bridge 
formed by Lys309. The Lys309 side chain has rotated and forms a new salt bridge with Gln54. 
In addition, Lys309 is involved in crystal contacts with the side chain of Asp202. The Pro306A 
mutation therefore may be stabilizing the two loops and promoting the crystallization of MtUGM 
complex structures.  
The comparison of the overall structures between the liganded and the previously reported 
unliganded MtUGM46 showed that they are highly similar, with a rmsd value of 0.6 Å for all 
equivalent Cα atoms, excluding the residues located at the mobile loops. The major difference is 
the closure of the mobile loops around the active site due to ligand binding. The binding of 
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ligand results in a large re-orientation of the α-helical domain-2 (residues Phe102-Asp194) 
(Figure 1C). The mobile loops 1 (Ala131-Asn140) and 2 (Gln167-Arg184) show a similar 
movement upon ligand binding as seen in other prokaryotic UGMs.40,41 The structural 
rearrangement upon ligand binding in MtUGM is far more profound. The structures were 
analyzed by DynDom67,71 and showed that mobile loop 1 (with adjacent helices α5 and  α6) and 
mobile loop 2 rotate ~32° and translate 0.7° towards the uridine-diphosphoryl moiety of the 
ligand resulting in a ~67% closure of the active site. The C-terminus of helix α4 (Ala127-
Glu132), helices α6 and α7 (Leu153-Trp166) and residues Ile178-Thr186 therefore function as a 
flexible hinge (Figure 1D). In addition, the rearrangement of mobile loop 2 results in formation 
of helix α8 (Ala175-Arg180), adjacent to the uridine-diphosphoryl moiety of the ligand. The 
closure of the active site will likely protect the reaction intermediates from the environment and 
potentially prevent the putative UDP intermediate from exiting the active site, as proposed for 
other UGMs.51,53,72 
 
Substrate binding induces local changes in MtUGM active site 
The structures of MtUGMox:UDP-Galp and MtUGMred:UDP-Galp are nearly identical, with a 
rmsd value of 0.3 Å for all equivalent Cα atoms. The FAD N5 atom is closer to the C1 atom of 
the Galp moiety (3.8 Å) compared to the MtUGMox structure (4.2 Å). The electron density of the 
Galp moiety is stronger in the MtUGMred complex structure. In the MtUGMox structure, there is 
visible sugar density only for molecule B whereas in the reduced structure, there is visible 
density for all 3 monomers. A similar trend was observed for DrUGM,51 and suggests the 
stabilization of the galactose orientation for catalysis.  
The crystal structures of both unliganded MtUGM and of the MtUGM:UDP-Galp complex 
structures enables determination of local structural changes that occur upon substrate binding. 
Figure 2A and Scheme 3 show the binding mode of MtUGM with UDP-Galp (additional details 
are included in the Supplemental Information). The positions of the majority of the active site 
residues remain unchanged when substrate binds. However, several active site residues change 
position in order for the substrate to bind in a productive binding mode and for the active site to 
close (Figure 2B). The conserved arginine (Arg180), located on the mobile loop, moves ~9.4 Å 
(Cα position) upon closure of the active site and interacts with the substrate through the 
pyrophosphate and Galp 2-OH and 3-OH groups (Figure 2B and 3A). The other conserved active 
site arginine, Arg292, has a different rotamer conformation in unliganded MtUGM. The 
guanidinium moiety of Arg292 rotates 180° when the substrate binds and interacts with the UDP 
β-phosphate and the O5 atom of the Galp moiety. The third strictly conserved arginine, Arg360 
at the FAD binding domain, interacts with the FAD phosphate in the unliganded structure and 
moves to the active site where it interacts, through a conserved H2O molecule, with both the 
pyrophosphate and the 2-OH of Galp. In addition, Arg360 helps positioning Tyr366. The side 
chain of Tyr366 rotates ~90° and shifts 5.4 Å with respect to its hydroxyl group to stabilize the β 
phosphate group of the UDP moiety. Furthermore, the aromatic ring forms a cation-π interaction 
with Arg180 and stabilizes the closed conformation of the enzyme.  
The uridine-ribose binding region shows the most dramatic structural rearrangements (Figure 
2B). Upon binding of the substrate, the side chain of Gln165 changes position to allow proper 
binding of the ribose moiety and the aromatic ring of Tyr161 rotates ~45° to form the cation-π 
interaction with the uracil.  Ile178 and Leu181 of the newly formed helix α8 (mobile loop 2) are 
adjacent to the uridine-diphosphate group and aid positioning the uracil-ribose moiety (Figure 
2B). Furthermore, the side chain of Trp166 rotates ~45° and interacts with the ribose hydroxyls 
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(Figure 3A) and with Leu173 of mobile loop 2. The rotation of the Trp166 side chain disrupts the 
cation-π interaction between Trp166 and Arg261, causing the Arg261 side chain to rotate 180° 
away from the substrate binding site. Nevertheless, this new orientation is stabilized by 
interactions with the main chain carbonyl of Gln165, the side chains of Gln167 and Ser317 
(Figure 3A and B), and with Phe319, that rotates ~45° to form a new cation-π interaction. In 
addition, the C-terminus of β14 (Ser317-Phe319) and the connecting loop (Ala320-Pro326) have 
moved closer to the FAD binding site (Figure 3B). This loop movement triggers repositioning of 
Arg360 towards the active site to prevent a clash with Pro326. The Ser317-Glu321 segment is 
also functioning as part of the flexible hinge (Figure 1D).  
 
Potential roles of Trp166 and Arg261 in regulating prokaryotic UGM domain closure 
Trp166 and Arg261 are strictly conserved among prokaryotic UGM and are found on the edge 
of the active site cleft. Figure 3 shows the superposition of open unliganded MtUGM structure 
with the closed MtUGM:UDP-Galp complex structure. Trp166 is located at the C-terminus of 
helix α7 and the beginning of mobile loop 2. Arg261 is located above the C-terminus of helix α7 
and is part of the FAD binding domain. Trp166 and Arg261 may act as a switch to maintain the 
active site in a locked and fully open conformation by forming a cation-π interaction between the 
two residues, as found in unliganded MtUGM and in molecule B of unliganded EcUGM.46,50 
Substrate binding, with concomitant rotation of Trp166 and disruption of the cation-π interaction 
presumably triggers the closure of the active site. In the open conformation, where Trp166 and 
Arg261 form the cation-π interaction, the closure of mobile loop 2 would result in a steric clash 
between Leu173 and Trp166 (Figure 3A). Indeed, the analysis of the semi-closed and closed 
conformations described for other liganded and unliganded prokaryotic UGM structures show 
that the cation-π interactions between the strictly conserved tryptophan and arginine residues are 
broken and that these two residues are found in the same orientation as in the liganded 
MtUGM.40,41,46,50,51 This evidence suggests that the conserved tryptophan and arginine residues 
play key roles in regulating prokaryotic UGM domain closure. 
 
 
Analysis of the binding modes of the four UGM ligands 
 
MtUGM:UDP complex structure 
The crystal structure of MtUGM:UDP was determined to 2.5 Å resolution. All 3 monomers 
are identical and contain bound UDP and oxidized FAD. The overall structure of MtUGM:UDP 
complex is highly similar to that of MtUGM:UDP-Galp complex (rmsd less than 0.4 Å). UDP is 
bound in the closed conformation and makes the same interactions in the active site as seen for 
the UDP moiety of the substrate UDP-Galp (Figure 5A and B). The galactose binding pocket is 
filled with water molecules that are nicely accommodated in the absence of the sugar moiety 
(Figure 5A). The observed closed conformation of the active site indicates that the binding of the 
UDP moiety is enough to promote closure of the active site, as we previously reported.51  
 
UDP-Galp (1) binding is similar to other prokaryotic UGMs 
The similarities in the substrate binding between MtUGM and other prokaryotic UGMs reveal 
a conservation of the binding site. A structure-based sequence alignment of MtUGM with other 
known prokaryotic UGMs is shown in Supplemental Figure S2.  
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Superposition of monomer B from the reduced MtUGM:UDP-Galp and DrUGM:UDP-Galp 
complex structures reveals that 361 residues overlap with a rmsd of 1.3 Å. The substrate is bound 
in an identical position and orientation in both complexes, with its Galp moiety close to the 
isoalloxazine N5 and makes identical interactions in the sugar-phosphate-ribose binding regions 
as observed in the DrUGM:UDP-Galp complex51 (Figure 4A and B). However, although the 
interactions in the uridine binding pocket are not strictly conserved (Figure 4B), this binding 
pocket is predominantly hydrophobic in both structures. On one side of the pocket, the uracil is 
stacked against a strictly conserved tyrosine residue (Tyr161). In addition, the O4 atom of the 
uracil moiety is anchored by both conserved Asn282 and non-conserved Asn284. The other side 
is aligned by the hydrophobic residues Phe102, Val158, Ile178 and Leu181. These residues are 
not strictly conserved among prokaryotic UGM and help in positioning the uridine moiety when 
the active site closes.  
 
MtUGM:UDP-F4-Galp (3) complex structure 
The crystal structure of MtUGM:UDP-F4-Galp 3 was determined to 2.25Å resolution. The 
increased affinity of UGM for the deoxyfluorinated UDP-Galp compared to the unfluorinated 
UDP-Galp is manifested in the improved electron density for the F4-Galp moiety in this 
structure.  All 3 monomers contain bound UDP-F4-Galp 3 and oxidized FAD. Monomers A and 
B display the closed conformation. Monomer C is found in the open conformation, with two 
alternate conformations of the active site mobile loop (open and closed). Superposition of 
monomer A from MtUGM:UDP-Galp and monomer A of MtUGM:UDP-F4-Galp complex 
structures reveals that all 390 residues nicely overlap with a root mean square deviation of less 
than 0.3 Å. Thus, the binding mode of UDP-F4-Galp 3 is strikingly similar to that of UDP-Galp 
(Figure 6B). As expected, the F4-Galp conformation only shows minor distortions from a 4C1 
conformation.73 However, the presence of the fluorines at the C2 and C3 positions of the 
galactopyranose ring induces changes in the pyranose ring orientation (Figure 6A and 6B). 
Compared to the unfluorinated Galp, the dideoxy-tetrafluorinated Galp is tilted 0.5 Å at its C2, 
C3 and C4 carbon atom positions. In this presentation mode, the tetrafluorinated sugar moiety is 
in closer contact with the FAD isoalloxazine ring. As a result, the N5 of the isoalloxazine ring of 
FAD is pushed away and is buried about 0.9 Å deeper into the FAD binding pocket. 
Interestingly, although this displacement causes the O4 carbonyl atom of the isoalloxazine ring 
to shift ~0.8 Å, the hydrogen bond with the C4 hydroxyl group of F4-Galp is still kept.  
Scheme 4 shows the direct contacts between the fluorine atoms and MtUGM (additional 
details are included in the Supplemental Information). The C2 axial fluorine (F2β) displays a 
close contact (2.3 Å) with the O4 carbonyl of the isoalloxazine ring and additional interactions 
with the carbonyl oxygen (3.3 Å) of Ala64. In addition, the C2 equatorial fluorine (F2α) directly 
interacts with the guanidinium of Arg180 and, through a conserved water molecule, with Arg360 
and Asp368 (The F…OH2 distance is 3.7 Å), similar to the interaction between the C2 hydroxyl 
group and enzyme in the UDP-Galp structure. The CF2 group at the 3-position is located within a 
hydrophobic environment formed by the aromatic rings of Tyr191 and Phe192. The distance of 
the C3 equatorial fluorine (F3β) to Cφ of Phe192 (3.7 Å) is similar to that observed for the C3 
hydroxyl group of Galp in the corresponding complex. The C3 equatorial fluorine (F3β) largely 
interacts with the O4 carbonyl of the isoalloxazine ring (dF…O = 2.6 Å), while the F3α group 
establishes interactions with the α-phosphate moiety, through a conserved water molecule (The 
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F…O distance is 3.2 Å to the water molecule). Strikingly, three out of the four fluorine atoms of 
UDP-F4-Galp 3 display very close distances (from 2.2 to 3.2 Å) to the cofactor O4 carbonyl.  
Comparison of molecule C (open form) with the closed UDP-F4-Galp 3 complex structure 
reveals that the α-helical domain (domain 2) is in the open conformation, similar to that 
described for the unliganded MtUGM structure. Given the open conformation of the α-helical 
domain, the uracil moiety is less tightly bound. As mentioned above, the active site mobile loop 
(loop 2) is found in two alternative positions (both open and closed). In the open form, this 
mobile loop makes no contacts with the ligand. In contrast, in the closed conformation, the loop 
still provides the same interactions as in the closed monomers. The positions of most of the 
active site residues and UDP-F4-Galp 3 in this conformation remain largely unchanged and 
provide analogous interactions to those described above (Figures 6C and 6D). The only two 
residues that significantly changed their positions are Tyr366 and Arg360, which now display 
orientations similar to those seen in the unliganded MtUGM structure. Presumably, the additional 
strain on the FAD isoalloxazine ring described above triggers the domain opening to release the 
clash introduced by the C2 axial fluorine (F2α, at 2.7 Å in closed conformation). Due to this 
rearrangement, Tyr366 is now unable to be hydrogen bonded to the β-phosphate, resulting in a 
rotation of the β-phosphate and the F4-Galp moieties around the O3 atoms of α-phosphate and β-
phosphate, respectively (Figure 6C and 6D). These conformational changes result in a final 
position of the C2 axial fluorine F2β at 3.4 Å from the N5 of the FAD isoalloxazine ring. 
 
MtUGM:UDP-F4-Galf complex structure 
The crystal structure of MtUGM:UDP-F4-Galf 4 was also determined to 2.4 Å resolution. 
Importantly, this is the first reported UGM complex structure with a bound hexafuranose sugar.  
All three monomers contain bound UDP-F4-Galf 4 and oxidized FAD. The 3 monomers are 
basically identical (average root mean square deviation of 0.2 Å for all atoms). The conformation 
and interactions of the UDP moiety of the inhibitor is identical to that of the other MtUGM 
complexes already described. The F4-Galf moiety of 4 is in a similar position and orientation as 
that observed for the Galp moiety of 1 and establishes major contacts with the re face of the FAD 
isoalloxazine ring (Figure 7A, 7B and Scheme 5). Noteworthy, the anomeric carbon atom (C1) 
of UDP-F4-Galf is positioned 4.4 Å from the FAD N5 atom, a distance that is likely too far for 
covalent catalysis (additional contact details are included in the Supplemental Information). 
However, it should be noted that these structures have been obtained under non-reducing 
conditions (oxidation of flavin occurring in the course of crystallization) and we cannot rule out 
that this distance is an artifact of these conditions and the substrate is positioned closer to the 
cofactor. In support of this, in all cases where bacterial UGMs have been crystallized with 
substrate (DrUGM51, KpUGM40 and this work), the distance between N5 of FAD and the 
anomeric carbon decreases upon reduction of the cofactor.  Unfortunately, a reduced FAD 
complex between MtUGM and UDP-F4-Galf was not successfully determined. 
The C2 β-fluorine F2β is fairly close to the N5 (2.7 Å) and O4 carbonyl atoms (3.1 Å) of the 
FAD moiety. The analysis also indicated that F2β displays additional contacts through 
structurally conserved water molecules with the polar side chains of Arg360, Asp368 and His68. 
Indeed, in this presentation mode, in the reduced state of the cofactor, the C2 β-fluorine F2β 
would clash with the cofactor.  Interestingly, the C2 α-fluorine F2α of UDP-F4-Galf 4 is found in 
the same position as the C3 axial fluorine F3α of UDP-F4-Galp 3 (Figure 7C) and provides the 
same interactions with the enzyme. The C3 β-fluorine F3β of UDP-F4-Galf 4 is in a similar 
Page 12 of 48
ACS Paragon Plus Environment
Journal of the American Chemical Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
13 
 
position as the C4 axial hydroxyl group of UDP-Galp, although the C3 carbon atom of 4 is tilted 
about 1.4 Å with respect to the C4 carbon of 1. The position of the F3β fluorine is shifted by 
about 1.9 Å with respect to the C4 hydroxyl group, and, as with F2β, makes contacts with the O4 
carbonyl of the isoalloxazine ring, as well as with the carbonyl oxygen of Ala64 (as described 
above for F2β of 3). This observed shift is likely induced by the electrostatic interaction with the 
O4 carbonyl of the isoalloxazine ring, and to minimize the possible steric contacts of the C3 α-
fluorine F3α with Leu66, His89 and with the aromatic ring of Phe192. Otherwise, the C3 α-
fluorine F3α would point in the direction of the C4-equatorial hydrogen in UDP-Galp 1.  
N’Go et al.37 have reported that UDP-F4-Galf 4 adopts a high energy conformation (4E) in its 
MtUGM-bound state, as evidenced by a H1-H4 nOe crosspeak obtained by a TRNOESY 
experiment, as opposed to the minimum energy conformation adopted in the free state (3T2). This 
in solution NMR-based observation is now confirmed by the X-ray crystallographic data 
obtained in this study.  
 
Common binding features of the 3 nucleotide-sugars 
Inspection of the structures of UGM bound to 1, 3 and 4 clearly show that the binding mode 
of the three molecules is basically the same: 1) the three UDP moieties are essentially identical in 
orientation, they interact with the same amino-acids, and display the same conformation;  2) in 
all cases, the endocyclic oxygen of the galactose ring points away from the FAD cofactor, thus 
exposing the C2-C3 side of the galactose residue to the cofactor. Moreover, in all the oxidized 
structures, the distance between the anomeric carbon atom and the FAD N5 atom is always 
above 4.2 Å, a surprisingly long distance for a mechanism involving covalent catalysis.  This 
distance shortens to 3.9 Å for the UDP-Galp structure with reduced cofactor.  In fact, for the four 
structures, the FAD N5 atom is always significantly closer (< 4.0 Å for the oxidized structures 
and 3.2 Å for the reduced structure) to the C-2 position of the galactose rings.  These results are 
consistent with the previous structures that all show a closer orientation of anomeric carbon with 
the N5 of FAD after reduction of the cofactor.40,51,53 
 
Comparison of the UDP-Galp:UGM and UDP-F4-Galp:UGM structures.  
Despite the extensive hydrogen bonding of the UDP-Galp sugar OH2 and OH3 groups, the 
drastic change of this vicinal diol moiety to a tetrafluorinated ethylene group clearly does not 
have a deleterious effect on the interactions with UGM residues in the binding pocket, despite 
the annihilation of any hydrogen bond donating capacity, and the reduced capacity to accept 
hydrogen bonds.74-76 The observed tilting of the pyranose sugar ring is the likely structural 
consequence from the new set of interactions of the tetrafluorinated moiety with the enzyme.  
It is interesting to observe that the fluorine atoms remain engaged in a great number of 
interactions, including those mediated by water (eg, the C2 equatorial fluorine (F2α) interacts 
with the guanidinium of Arg180 and, through a conserved water molecule, with Arg360 and 
Asp368, in an analogous manner to the interactions of the C2 hydroxyl group of Galp (The F…O 
distance is 3.7 Å).. The interaction of a C-F with water molecules is of great general interest 
given the ongoing debate regarding its hydrogen bond accepting capacity.74,76-79 To the best of 
our knowledge, few crystal structures showing water-mediated hydrogen bonds with a 
fluorinated carbohydrate have been reported.80,81 However, the fluorine atoms in these examples 
were CH-F groups, which are superior hydrogen bond acceptors as compared to the fluorine 
atoms within our CF2 fragment.74,75  
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The alcohol groups in UDP-Galp extensively interact with the FAD isoalloxazine ring. For the 
tetrafluorinated pyranose of 3, close contacts with three out of the four fluorine atoms are seen.  
Fittingly, an attractive orthogonal multipolar interaction, as defined by Müller and Diederich,82,83 
can be invoked between the C2-Fα bond with the FAD C4=O carbonyl (∠ F…C=O 70.7°; dC-F 
3.4Å). In the latter case, the C-F/C=O dihedral angle (θ= -173°) is also consistent with the 
existence of an attractive dipole-dipole interaction (Table S2).  
The C3-F2 group is located at a hydrophobic environment provided by two contiguous 
aromatic amino acids. Very probably, the existing interactions between the CF2 fragment and the 
enzyme are of stabilising nature, presumably due to hydrophobic desolvation. In fact, when 
compared to complexed 1, with a 3-OH group close to Phe192, it is likely that the binding of the 
CF2 moiety at this site should be favored. 
 
Comparison of the interactions of the furanoside 4 with pyranosides 1 and 3 
In general, based on the gathered structural data, there are fewer strong attractive H-bonds for 
the two pyranosides 1 and 3 compared to the furanoside 4 (See Schemes 3-5, and ESI). This fact 
may explain why furanosides (substrates or inhibitors) have always better affinity for UGM than 
the corresponding pyranoside analogs.29,31-34 The C5-OH of Galf is located in the same position 
as the C6-OH of Galp and forms one analogous hydrogen bond to His89. In addition, the C6 
hydroxyl group of Galf is anchored by Asn282, Tyr161 and Arg292, which also show one 
additional interaction with O4, resembling that with O5 of the Galp moiety. The C5 and C6 
carbon atoms of Galf are properly positioned to provide hydrophobic interactions with Tyr191, 
Val91, Val280 and Arg292. Globally, this strong set of attractive contacts at the vicinity of the 
C4-C5-C6 part of Galf 4 are absent in the pyranosidic substrate 1 and in the inhibitor 3. These 
observations likely explain why it was found, in a previous study, that the 6-fluoro-analogue of 
UDP-Galf was a poor UGM substrate with a dramatic loss of binding affinity.36 This fact was 
further verified with 6-deoxy analogs and UDP-L-arabinose (a UDP-Galf analogue without the 
6CH2OH group).84  
From these three structures, His89 is the common closest residue to the O4 and O5 positions 
of the sugar rings. This residue could play the role of proton relay during the catalytic process. 
Indeed, the reversible interconversion between 1 and 2 requires a proton transfer between the O-
5 and O-4 of the galactose moiety. 
The comparison of the observed interactions involving the fluorine atoms between the 
furanose and pyranose deserves further attention. The F2β fluorines of 3 and 4 are always the 
closest atoms to UGM (more precisely, to its cofactor), while the fluorine F3α is precisely the 
furthest one. However, the two carbohydrate rings are not interacting with the protein in the 
same way. For the pyranose 3, the F2α and the two β fluorine atoms are clearly interacting with 
the FAD moiety. In contrast, for the furanose 4, only the two β fluorines are in contact with the 
FAD cofactor.  It is also worth to mention that, for both galactose forms, the four fluorine atoms 
of 3 and 4 are always in close proximity to the oxygen atoms of the C=O carbonyls of FAD and 
Ala64. 
Given the fact that F4-Galp is bound in a similar conformation as the Galp moiety in UDP-
Galp, we may anticipate that the F4-Galf geometry represents a close representation of the actual 
binding mode of the Galf ring in the natural compound. However, due to the different 
interactions caused by substituting the C2 and C3 hydrogens with fluorine atoms, the furanose 
ring might be slightly tilted, as also observed for F4-Galp.  
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Comparison of furanosides 4 and 5 
From these structures, one can try to answer why the monofluorinated UDP-Galf analogue 5 
(Figure 1) displays poorer affinity for KpUGM than the tetrafluorinated analogue 4. Assuming 
both Galf analogs bind in the same mode to UGM, it can be safely hypothesized that the 
increased electron density of the fluorine atom F3β atom in 5 compared to the corresponding 
atom in 4 would result in strong(er) repulsive interactions with the O4 and N5 FAD atoms. This 
is in accord with empirical observations made by Dalvit and Vulpetti regarding the correlation of 
the fluorine chemical shift (shielded CHF fluorines being more electron rich than deshielded CF2 
fluorines) with the magnitude of repulsive dipolar/electrostatic interactions.85  
 
Conclusions 
The crystal structures reported herein provide the first examples of UGM from the pathogenic 
organism M. tuberculosis complexed with ligands and thus represent the first structures of 
ligands bound to this key antimicrobial drug target. These structures provide critical insights for 
further drug design and in silico docking studies. Combined with the previously reported 
unliganded MtUGM structure, these structures have also enabled us to detail the conformational 
changes that occur upon substrate binding. The previously reported prokaryotic structures 
complexed with ligands were less than ideal for these comparisons. In the case of DrUGM, there 
was no unliganded structure and, for KpUGM, the crystals were initially formed using UDP-
glucopyranose and then soaked with UDP-galactopyranose after the crystals were formed. As 
UDP-glucopyranose is a very poor inhibitor of UGM, it is likely that the structural changes noted 
for the KpUGM complexes did not represent the complete set of changes that take place in the 
real process. Herein, we have demonstrated that the binding of ligands and inhibitors indeed 
induces large and local conformational changes in the enzyme to allow the ligand to bind and the 
active site to close. Although the hinged closure of the active site has been alluded to in previous 
reports,50 this research describes the first direct observation of the hinged nature of the closure. 
The UDP moieties of all the structures bind in nearly-identical manners to MtUGM, with minor 
differences seen in the sugar binding regions.  
We have derived the first 3D-structure of a polyfluorinated carbohydrate analogue complexed 
with a protein. It is remarkable that for both the pyranoside and furanoside structures, the CF2-
CF2 motif is involved in multiple interactions with the enzyme, with or without water mediation, 
as well as multipolar interactions as described by Diederich et al.82 Our observations strongly 
suggest that the balance of the entropy and entalphy contributions associated to the hydrophobic 
desolvation effect of the tetrafluorinated system is favourable for the molecular recognition 
process. Though it is not possible to quantitatively compare all the interactions connected to the 
2CH(OH)-3CH(OH) groups of UDP-Galp 1 with those linked to the tetrafluorinated moiety in 3, 
these novel interactions are likely at the origin of the favorable binding process of these sugar 
analogs. Although merely speculative, it appears that the dideoxy-tetrafluorination modification 
results in both stabilizing enthalpic and entropic contributions to binding, as proposed for the 
binding of aromatic ligands to human carbonic anhydrase.86,87 
This study thus validates, in a structural manner, that the polar and hydrophobic character of 
polyfluorinated groups such as CF2-CF2 can improve the contacts between a carbohydrate 
analogue and its host-protein in a significant manner. The possibilities of polyfluorination of 
carbohydrates have not been extensively investigated compared to the other main classes of 
biomolecules.38,39,88  For instance, polyfluorination of aromatic amino acids has been explored to 
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enhance protein stability89,90 and to promote the formation of β-peptides bundles.91 
Polyfluorinated aromatic ligands have also been exploited to discover novel attractive 
organofluorine-protein interactions92 and, more recently, to address the key question of the 
hydrophobic effect that underlies the binding of many ligands to proteins.86 Trifluoromethylated 
and polyfluorinated lipids have also been exploited either as direct substrates of lipid- and 
glycolipid modifying enzymes.93 Although it has been recently shown than a CF2 moiety at the 
pyranose ring may restore the key exo-anomeric effect,94 to the best of our knowledge, the 
structural basis to justify the replacement of a carbohydrate vicinal diol for a polyfluorinated 
system in molecular recognition events has never been reported to date. These observations, 
along with the discovery of the hexafuranose binding mode to UGM, should now provide the 
impetus for the development of yet more potent inhibitors.  
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Table 1: Crystallographic Data 
1A: Data Collection      
Protein MtUGM  
UDP-Galp 
 (non-red) 
MtUGM 
UDP-Galp 
(re-red) 
MtUGM-UDP 
 
MtUGM 
UDP-F4-Galp  
MtUGM 
UDP-F4-Galf  
Beamline 08ID-1 08ID-1 08ID-1 08ID-1 08ID-1 
Space group C2 C2 C2 C2 C2 
Unit cell dimensions    a = 172.4 Ǻ, 
  b =99.5 Ǻ , 
     c =100.2 Ǻ 
α = 90.0° 
      β =110.8° 
γ = 90.0° 
a =171.2 Ǻ, 
b =99.5 Ǻ , 
   c =100.0 Ǻ 
α = 90.0° 
β =110.1° 
    γ = 90.0° 
a =176.5 Ǻ, 
b =101.2 Ǻ , 
  c =102.0 Ǻ 
    α = 90.0° 
β =109.2° 
   γ = 90.0° 
a =171.3 Ǻ, 
b =98.3 Ǻ , 
     c =100.5 Ǻ 
α = 90.0° 
β =109.9° 
γ = 90.0° 
a =173.6 Ǻ, 
b =100.4 Ǻ , 
    c =101.3 Ǻ 
α = 90.0° 
β =108.7° 
γ = 90.0° 
Resolution range (Å)                                         50.0-2.40
2.46-2.40 
50.0-2.60 
2.67-2.60 
45.5-2.50 
2.59-2.50 
50.0-2.25 
2.31-2.25 
50.0-2.55 
2.62-2.55 
# reflections 256460 170129 372716 295500 184896 
# unique reflections 61216 48236 58458 74331 53750 
redundancy      
% completeness 99.0(98.9) 97.8(98.7) 99.5(100) 99.8(99.9) 99.9(99.8) 
Rsym (%) 9.4(76.4) 7.3(82.0) 13.0(63.3) 9.7(87.4) 14.5(82.5) 
I/σ(I) 9.7(1.6) 11.3(1.7) 7.2(2.2) 9.4(1.7) 6.0(1.8) 
#molecules in ASU 3 3 3 3 3 
1B: Refinement      
Resolution range  (Å) 50.0-2.40Å 50.0-2.60 Å 45.5-2.50Å 50.0-2.25Å 50.0-2.55Å 
Rwork/Rfree (%) 19.5/ 23.7 20.7/ 24.9 18.5/ 21.9 21.2/ 25.4 19.2/ 24.1 
No. of amino acid 
residues 
3*392 3*391 3*392 3*391 3*391 
No. of solvent atoms 404 110 284 427 319 
Ligands 3 * FAD 3 * FADH 3 * FAD 3 * FAD 3 * FAD 
     3* UDP-Galp    3 * UDP-Galp 3 * UDP    3 * UDP-F4Galp 3 * UDP-F4-Galf 
Rmds    
   Bond length (Å) 
   Bond angles  (°)                
Ramachandran (%)                      
Most favored             
Additionally allowed  
 
0.003 
0.775 
 
98.3 
      1.7 
 
0.003 
0.590 
 
96.6 
3.4 
 
0.002 
0.623 
 
98.2 
1.6 
 
0.002 
0.658 
 
97.2 
2.6 
 
0.004 
0.729 
 
97.4 
2.6 
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Table 2: Kinetic data for MtUGM and other bacterial UGM (KM measured for UDP-Galf). 
 
 kcat (s-1) KM µM kcat/KM 
(µM-1s-1) 
 
MtUGM(P306R) 
MtUGM(wildtype) 
7.5±0.5 
7.8±.2 
70±8 
45±3 
0.11±0.02 
0.17±0.06 
This work 
This work 
KpUGM 5.5±0.7 43±6 0.12±0.02 72 
EcUGM 27 22 1.22 95 
DrUGM 66±2.4 55±7 1.18 51 
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Scheme 1 – The UGM catalyzed pyranose/furanose interconversion and structures of fluorinated 
ligands. Kd’s have been measured by STD-NMR with UGM from K. pneumoniae.35,37 
 
Scheme 3 – Schematic interaction map of UDP-Galp 1 and MtUGM (d < 3Å). 
Scheme 4 - Schematic interaction map between UDP-F4-Galp 3 and MtUGM (contacts < 3Å 
have been represented). 
 
Scheme 5 - Schematic interaction map between UDP-F4-Galf 4 and MtUGM (contacts < 3Å 
have been represented). 
 
Figure 1: Structure of MtUGM complexed with UDP-Galp. A) Stereodiagram of the 
monomer from MtUGM, with numbering of the helices and sheets. The numbers correspond to 
the labels in Supplemental Figure 1, a structure-based sequence alignment. Domain 1 is colored 
blue, Domain 2 is coloured green and Domain 3 is colored grey. The mobile loops are colored 
yellow. FAD and UDP-Galp are shown as ball-and-stick representations. B) Ribbon 
representation of reduced MtUGM:UDP-Galp dimer. Individual subunits are colored green and 
blue. FADH2 and UDP-Galp are shown in stick representation. C) Superposition of unliganded 
MtUGM (blue) and MtUGM:UDP-Galp complex (green). Open conformation of domain 2 with 
mobile loops I and II shown in yellow. Closed conformation of domain 2 (red) with mobile loops 
I and II shown in magenta. FAD and UDP-Galp are shown in stick representation. D) 
Stereodiagram representation of the domain 2 movement of MtUGM as it transitions from 
unliganded (open) and UDP-Galp bound (closed, black) form as identified by Dyndom. The 
hinge regions (green) are responsible for movement of the α-helical domain (red) upon ligand 
binding and active site closure with respect to fixed β-sheet and FAD domains (blue). 
  
Figure 2: A) MtUGM with bound UDP-Galp. UDP-Galp, FAD and residues within 4Å are 
shown as sticks. Feature enhanced maps (FEM), 2mFo-DFm-sigmaA weighted electron density 
maps for the ligands (contoured at 1σ) is shown as a blue wireframe. B) Stereodiagram of 
unliganded MtUGM (blue) superimposed on MtUGM:UDP-Galp (red, yellow). Moving mobile 
loop 2 residues labelled according to monomer colour.  
 
Figure 3: Trp166 and Arg261 regulate domain closure. 
Superposition of unliganded MtUGM (open, blue) and MtUGM:UDP-Galp complex (closed, 
red). A) Open conformation with Trp166 and Arg261 forming the cation-π interaction. Closed 
conformation Trp166 side chain rotates ~45° and disrupts the cation-π interaction with Arg261. 
Arg261 side chain rotates 180° around its Cγ atom away from the substrate binding site.   
B) The C-terminus of β14 (Ser317-Phe319) and connecting loop (Ala320-Pro326) move closer 
to the FAD binding site. The loop movement triggers repositioning of Arg360 towards the active 
site to prevent a clash with Pro326. In addition, Arg360 helps positioning Tyr366. 
 
Figure 4: Comparison of the active sites from MtUGM:UDP-Galp (blue) and DrUGM:UDP-
Galp (red). Labeling of active site residues is according to MtUGM sequence. A) Overlay of 
MtUGM:UDP-Galp (blue) and DrUGM:UDP-Galp (red). UDP-Galp is bound in the identical 
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position and orientation with its Galp moiety close to the isoalloxazine N5 and makes identical 
interactions in the sugar-phosphate-ribose binding regions. B) Overlay of MtUGM:UDP-Galp 
(blue) on DrUGM:UDP-Galp (red). The interactions in the uridine binding pocket are not strictly 
conserved between MtUGM and DrUGM. 
 
Figure 5: Binding mode of inhibitor UDP. A) MtUGM with bound UDP. Sugar binding pocket 
is filled with water molecules (purple spheres) to accommodate for the lack of the sugar moiety. 
B) Superposition of MtUGM with bound UDP (B, blue) on MtUGM:UDP-Galp (B, red). The 
binding mode of UDP is the same as the binding mode of the UDP moiety in UDP-Galp crystal 
structure. Ligands and residues within 4Å are shown as sticks. Feature enhanced maps (FEM), 
2mFo-DFm-sigmaA weighted electron density maps for the ligands (contoured at 1σ) is shown 
as a blue wireframe. 
 
Figure 6: Binding mode of inhibitor UDP-F4-Galp. A) MtUGM with bound UDP-F4-Galp. B) 
Superposition of MtUGM with bound UDP-F4-Galp (B, blue) on MtUGM:UDP-Galp (B, red). 
Compared to the unfluorinated Galp moiety the dideoxy-tetrafluorinated Galp moiety is tilted 
about 0.5 Å at its C2, C3 and C4 carbon atoms. In addition, the exchange of the C2 axial 
hydrogen atom of Galp by fluorine results in steric repulsion of the isoalloxazine ring of FAD.  
C) MtUGM with bound UDP-F4-Galp with open conformation of domain 2. D) Superposition of 
MtUGM with bound UDP-F4-Galp (C, red) on MtUGM:UDP-F4-Galp (B, blue). The position of 
Tyr366 and Arg360 with are now in a position similar to unliganded MtUGM. The β-phosphate 
and F4-Galp moiety are rotated around the 03 atoms of α-phosphate and β-phosphate 
respectively. Ligands and residues within 4 Å of the ligands are shown as sticks. In panel A & C, 
the Feature Enhanced Map (FEM), 2mFo-DFm-sigmaA weighted electron density map for the 
ligands (contoured at 1σ) is shown as a blue wireframe. 
 
Figure 7: Binding mode of inhibitor UDP-F4-Galf. A) MtUGM with bound UDP-F4-Galf.  The 
F4-Galf moiety is in a similar position and orientation as observed for the Galp moiety and binds 
at the re face of the FAD isoalloxazine with the anomeric carbon atom (C1) positioned 4.3 Å 
from the FAD N5 atom. Ligands and residues within 4 Å are shown as sticks. The Feature 
Enhanced Map (FEM), 2mFo-DFm-sigmaA weighted electron density map for the ligands 
(contoured at 1σ) is shown as a blue wireframe. B) Superposition of MtUGM with bound UDP-
F4-Galf (B, blue) on MtUGM:UDP-Galp (B, red). C) Superposition of MtUGM with bound 
UDP-F4-Galf (B, blue) on MtUGM:UDP-F4-Galp (B, red). The F4-Galf moiety is in a similar 
position and orientation as observed for the Galp moiety 
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